A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Trial Profile

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals; Verastem Oncology
  • Most Recent Events

    • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
    • 12 Dec 2017 Results assessing dual effects in TCL cohort from a Phase 1, open-label study of Duvelisib in patients with relapsed or refractory T-cell lymphomas along with in vitro and in vivo models of TCL, were published in the Blood.
    • 30 Nov 2017 Results assessing safety and efficacy published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top